Why Allergists Don't Recommend Allergy Drops | Curex

Quick Answer

Your allergist likely won't prescribe sublingual drops for three intersecting reasons: ACGME fellowship training doesn't specifically mandate SLIT education, the AAAAI/ACAAI only endorse FDA-approved SLIT tablets (not off-label drops), and allergy shots generate 3–5 times more revenue per patient than drops. In Europe, where these financial incentives don't apply, SLIT accounts for 40–45% of all immunotherapy prescriptions. The 2025 evidence consensus states "near equivalent efficacy, superior SLIT safety profile" (Bernstein).

Quick Facts

Detail	Info
Allergist SCIT revenue per patient	$1,700–2,700/year (Year 1); $650–1,300 maintenance
SLIT revenue per patient	$300–600/year
Revenue gap	3–5× higher for shots vs. drops
Immunotherapy share of practice revenue	40–60%
European SLIT adoption	40–45% of all immunotherapy
Patient drops cost	$39–99/month; allergist SCIT = $1,700–2,700/year per patient (2026)

"My Allergist Said Drops Aren't Proven — Is That True?"

You walked into your allergist's office expecting options. You'd read about sublingual drops — daily treatment at home, no weekly injections, fewer severe reactions. Your allergist nodded, then steered the conversation firmly toward shots. When you asked about drops specifically, you heard some version of: "not enough evidence," "not FDA-approved," or "I can't recommend them."

You left confused. If drops work in Europe, if the FDA has approved SLIT tablets, and if studies show comparable efficacy — why does your allergist seem opposed? The answer involves training, economics, and a regulatory gap that affects patient access more than patient safety.

Why This Happens — Training, Money, and Regulation

Step 1 — Fellowship training prioritizes shots. ACGME-accredited allergy/immunology fellowships don't specifically mandate SLIT training. While 73% of allergists report some SLIT "experience" since 2014, SCIT training sits at 90.7%. Most allergists are simply more comfortable prescribing what they were trained to administer. Comfort drives prescription patterns more than evidence does.

Step 2 — The revenue math strongly favors in-office shots. Allergy shots generate $1,700–2,700 per patient in Year 1 and $650–1,300 annually during maintenance — all administered in-office. SLIT generates $300–600 per patient per year, taken at home. Immunotherapy accounts for 40–60% of a typical allergy practice's total revenue. Recommending home-based drops means redirecting thousands of dollars per patient per year out of the practice.

Step 3 — The official position creates a narrow window. The AAAAI/ACAAI 2017 joint statement endorses only FDA-approved SLIT tablets — Grastek (grass), Ragwitek (ragweed), Odactra (dust mite), and Oralair (grass mix). Off-label multi-allergen drops are described as "not systematically studied." This creates a practical problem: 50–80% of allergy patients are polysensitized (allergic to multiple things), but FDA-approved tablets each target a single allergen. European guidelines, working from the same evidence base, reach broader SLIT endorsement.

What To Do Next

Step 1 — Understand what the evidence actually says. The 2025 consensus (Bernstein) concludes "near equivalent efficacy, superior SLIT safety profile" when comparing sublingual to subcutaneous immunotherapy. SLIT has documented anaphylaxis rates orders of magnitude lower than SCIT. The evidence gap your allergist cites is primarily about multi-allergen formulations, not the sublingual mechanism itself.

Step 2 — Ask your allergist the specific question. Instead of "do you offer drops?" ask: "Given my specific allergen profile, am I a candidate for any FDA-approved SLIT tablet?" If you're allergic to grass, ragweed, or dust mites, an FDA-approved option exists. If your allergist still declines, ask for the clinical reasoning in writing — this distinguishes evidence-based caution from preference-based resistance.

Step 3 — Explore providers who specialize in SLIT. Telehealth allergy clinics and multi-allergen SLIT providers exist specifically because traditional allergist practices underserve this treatment modality. A quiz can identify your allergen profile and match you with providers who offer sublingual protocols for your specific triggers.

Take the free 3-minute allergy quiz →

When Your Allergist's Caution Is Actually Warranted

Your allergist's hesitation is genuinely evidence-based in specific scenarios: if you have severe uncontrolled asthma (SLIT labels contraindicate this), if you need venom immunotherapy (SLIT is not established for venom), or if your primary allergen has no well-studied sublingual formulation.

The polysensitization problem is real — 50–80% of patients react to multiple allergens, and FDA-approved tablets each target one. Off-label multi-allergen drops have growing evidence but less regulatory scrutiny. Your allergist may reasonably prefer the more established SCIT route for complex multi-allergen patients.

Where the caution crosses into bias: dismissing SLIT entirely for single-allergen patients who have FDA-approved tablet options, or framing home-based treatment as inherently unsafe when SLIT's safety profile is documented as superior to SCIT across all major studies.

Related Issues to Check

Allergy drops vs. allergy shots — A direct efficacy, safety, cost, and convenience comparison using current data, so you can evaluate the tradeoffs your allergist may not present neutrally.
Are allergy drops FDA-approved? — The regulatory landscape is more nuanced than "yes or no." Understanding which products have FDA approval and which are off-label helps you ask better questions.
Allergy drops cost per month — Comparing what you'd pay for drops vs. what the practice earns from shots puts the financial incentive in concrete terms.

Frequently Asked Questions

Are allergy drops as effective as shots? The 2025 evidence consensus (Bernstein) describes "near equivalent efficacy" between SLIT and SCIT. For specific FDA-approved tablets (grass, ragweed, dust mite), randomized controlled trials show 20–35% symptom reduction beyond placebo — comparable to SCIT ranges.

Why does Europe use drops so much more? In Europe, SLIT represents 40–45% of immunotherapy prescriptions. European regulatory frameworks approved sublingual products earlier, reimbursement structures don't tie practice revenue to in-office administration, and clinical guidelines adopted SLIT evidence faster than US professional organizations.

Is my allergist financially motivated to recommend shots? Immunotherapy accounts for 40–60% of allergy practice revenue, and SCIT generates 3–5× more per patient than SLIT. This doesn't mean your allergist is acting in bad faith — but it does mean the financial incentive and the clinical recommendation point in the same direction, which warrants independent evaluation.

Can I ask my allergist to prescribe drops off-label? You can ask. Off-label prescribing is legal and common in medicine. However, your allergist is not obligated to prescribe outside their comfort zone. If they decline, seeking a second opinion from a SLIT-focused provider is reasonable and appropriate.

Should I worry about safety without my allergist's oversight? SLIT has a documented superior safety profile compared to SCIT. The first dose must be supervised, and epinephrine is prescribed to all patients. Serious adverse events are extremely rare — estimated at 1 per 100 million doses for anaphylaxis. Home administration is the standard protocol, not a shortcut.

What if I'm allergic to multiple things — do drops still work? This is the legitimate limitation. FDA-approved tablets target single allergens. Multi-allergen off-label drops are widely used but have less rigorous trial data. If you're polysensitized, discuss whether sequential single-allergen treatment or multi-allergen formulations better suit your profile.

Last reviewed: March 2026 · Sources verified against current data

Medically reviewed by Dr. Chet Tharpe, MD · March 2026

Take the Next Step

Your allergen profile determines which treatment options — drops, tablets, or shots — fit your specific situation. A 3-minute quiz identifies your triggers and matches you with evidence-based options.